Working virtually is more important now than ever before.
The invisible threat of a new virus is currently looming overhead. In this uncertain time, we’re making sure healthcare works for the patients it serves.
A Letter from our CEO
As we navigate through the uncertainty, anxiety, and challenges of the COVID-19 (coronavirus) health emergency, I want to stress PRA Health Sciences’ leadership role and the actions we are taking to fight against COVID-19. We will continue to be diligent as we take coordinated actions and implement safeguards to ensure the health, safety, and well-being of our patients, families, customers, partners, employees, and the global community. We are waging this battle with you in mind—you are our highest priority.
As a leading CRO and healthcare intelligence company, PRA performs vital, life-saving work around the globe. The health of the patient is why we do what we do every day. As a result of the COVID-19 outbreak, many potential challenges could lead to difficulties in conducting clinical trials. These include travel limitations, quarantines, site closures, and concerns of site personnel or trial participants becoming infected with the coronavirus.
Fortunately, PRA has long been at the forefront of developing tools and technology that make participating in clinical trials more convenient and less burdensome to patients.
It is inspiring to see individuals, neighbors, communities, and nations come together in this time of need, and PRA is proud of the role we play in this global effort. We are committed to supporting you and caring for patients throughout this unique time in world health history.
Please continue to support your government guidelines to eradicate this virus and know that PRA’s teams of clinical research and healthcare intelligence experts are working tirelessly for you in the fight to eradicate COVID-19.
— Colin Shannon, CEO
PRA Health Sciences is a global healthcare intelligence partner, consistently ranked among the top CROs worldwide. We help develop lifesaving and life-improving drugs with our comprehensive clinical development services, including data management, statistical analysis, clinical trial management, medical writing, and regulatory and drug development consulting.We can help you through this difficult time. Learn more.
Recent developments regarding the spread of the Novel Coronavirus (COVID-19) have amplified the challenges our industry is currently facing.
PRA’s Mobile Health Platform (MHP) is the ultimate study support—anytime, anywhere.
In response to the global COVID-19 pandemic and with many locales either recommending or enforcing reduced external interactions, it will be increasingly difficult for patients to see their designated medical professionals/investigators in person or adhere to clinical study protocols requiring site visits. PRA’s Mobile Health Platform (MHP) provides patients with a way to connect with their providers so that clinical trial visits can proceed during the pandemic. Specifically, the mobile app can be used in clinical research as a patient monitoring tool during trials.
The mobile application features an administrative web app for sites and a downloadable mobile app for patients, enabling sites and patients to:
- eConsent/Re-Consent patients for use of the mobile application
- Collect consent forms from patients to allow for delivery of investigation product through a third party courier
- Remotely schedule and conduct video consults with patients
- Leverage mobile survey tools to provide real-time insights to study investigators for potential action.
We can monitor COVID-19 and provide insights about it remotely
Care Innovations, a PRA Health Sciences Company, is offering their Health Harmony COVID-19 Monitoring Program to allow employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.
By downloading the program’s app on their personal mobile devices, participants in the program will be able to report key health metrics related to COVID-19 such as body temperature, heart rate and pulse oximetry. In addition, participants report on symptoms of COVID-19 like shortness of breath, fatigue and changes in coughing. Participants benefit from PRA’s nurse-led clinical call center staff, who monitor the information reported through the app on a daily basis. The trained staff can address physical symptom, as well as the social and psychological impacts they may be experiencing.
Care Innovations has created three different programs, designed to address different individual needs regarding the virus:
- An educational program for people who show no symptoms
- A quarantine program for people who have been exposed to the virus
- An in-depth monitoring program for people who have been diagnosed with the virus
These solutions allow for a better understanding of how to manage your entire organization, regardless of whether or not it’s been exposed to COVID-19. Each program is designed to help empower members of your organization to educate themselves on the virus and know when help is needed.Learn how Health Harmony can aid in understanding COVID-19.
Safety monitoring doesn’t stop at approval
We offer pharmacovigilance services for COVID-19 vaccines and therapeutics.
With thousands of COVID-19 vaccines, therapies, and new and complex modalities under research around the world, drug developers are in an extraordinarily unique environment that requires speed, accuracy, and transparency of pharmacovigilance and safety data monitoring.
PRA offers full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-authorization safety studies (PASS) delivered by Real World Solutions.
We’re in this together. We Are PRA.
We’re leveraging our entrepreneurial mentality, agile infrastructure, data-driven insights, and patient-centric approach to transform clinical research into an accessible, reliable, and convenient care option for patients, caregivers, and their loved ones.
The work we do has a global impact. We’re fully committed to making it a positive change worldwide.
Including Children in COVID-19 Trials: Challenges and Opportunities
You may have heard the buzz surrounding a new severe inflammatory condition observed in children that seems to be connected with COVID-19 infection.…
In the first week of December, Industry Watch brings our readers news of promising developments in oncology. There’s a machine learning method being…
5 Ways to Maintain Regulatory Consistency During a Global Pandemic
Governments and businesses around the world continue to respond to the rapidly evolving COVID-19 disease, caused by an outbreak of a novel…